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Background: Effervescent calcium carbasalate is a buffered calcium-salt of acetylsalicylic acid (aspirin) prescribed to many cardiovascular 
patients. In healthy controls it has shown to cause less local gastric damage compared to plain aspirin at high doses. However, the benefit of low-
dose buffered aspirin on gastrointestinal symptoms remains unknown. The aim of this study was to investigate the prevalence of gastrointestinal 
symptoms in a population based cohort using low-dose plain or buffered aspirin.
Methods: A total of 50,000 surveys were sent to a national representative part of adult Dutch inhabitants in December 2008. Questions 
about demographics, gastrointestinal symptoms, medication use and co-morbidity were stated. Exclusion criteria were malignancy, inflammatory 
bowel disease, celiac disease and pregnancy. The prevalence of gastrointestinal symptoms in persons using acetylsalicylic acid (plain aspirin) or 
effervescent calcium carbasalate (buffered aspirin) were compared.
Results: A total of 18,116 (response rate 36%) surveys were returned of which 775 were excluded leaving 17,341 surveys for analyses. Of these, 
908 persons (5.2%) used plain aspirin and 604 persons (3.5%) buffered aspirin. The prevalence of gastrointestinal symptoms was 26.0% and 25.8% 
in plain and buffered aspirin users respectively, with no significant difference between both variants (odds ratio 0.99; 95%CI 0.78-1.25; p=0.92). 
After correction for multiple predictive variables this lack of difference remained (adjusted odds ratio 0.89; 95%CI 0.64-1.24; p=0.48).
Conclusions: The prevalence of dyspeptic complaints among low-dose aspirin users in the Dutch population is 26%. There is no significant benefit 
of buffered aspirin compared to plain aspirin regarding gastrointestinal symptoms.
